Menglu Ouyang, PhD, MPH, BN, The George Institute for Global Health, University of New South Wales, Sydney, Australia, shares an update on the INTERACT3 (NCT03209258) and INTERACT4 (NCT03790800) clinical trials, both looking to improve outcomes after intracerebral hemorrhage (ICH) with blood pressure (BP) control. INTERACT3 is an ongoing multicenter, stepped wedge, cluster-randomized trial assessing the effectiveness of a care bundle compared to standard of care. The intervention bundle includes early intensive BP lowering, glycemic control, treatment of pyrexia, and reversal of anticoagulation. The trial is underway across eight low- and middle-income countries and results are expected in the first half of 2023. The INTERACT4 study is assessing the effects of ambulance delivered intensive BP lowering in patients with acute stroke. Over 2000 patients will be enrolled to test the feasibility and clinical value of very early BP lowering, as well as the safety in patients with stroke mimics. This interview took place at the World Stroke Congress 2022 in Singapore.